CLSTN2

Across TCGA pan-cancer cohorts, CLSTN2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CLSTN2 data layer compared with 23 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CLSTN2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CLSTN2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where CLSTN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.694	0.274	.009	20	view →
CCRCC	DFS	Median	II,III,IV	0.171	0.819	.010	8	view →
GBM	OS	Median	All	0.637	0.427	.022	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CLSTN2–PDAC (OS)

Open the PDAC breakdown →